Background -The results of thymectomy on patients with generalised myasthenia gravis have been widely reported. However, there is no information on whether the experience ofwestern countries can be generalised to the population ofthe Middle East. The purpose of this study was to evaluate the safety and efficacy ofthymectomy in patients with myasthenia gravis in a Middle East patient population and to identify clinical and histopathological factors associated with improved long term outcome of surgery. Methods -In a prospective study, sixty three patients (aged 1 5-51 years) were treated in two university teaching hospitals between 1984 and 1991 and followed up for a mean of four years. Close communication was established with neurologists to obtain early referral. Radical anterior mediastinal dissection through a median sternotomy was performed in all patients. The response was evaluated by modified Osserman's classification. Results -Eighteen patients achieved complete remission and a further 39 improved, producing an overall response rate of 90'5%. Patients with milder disease (stage II) had a higher response rate (97%) than those with more advanced disease (78%). Patients operated on with less than three years of symptoms had a better outcome (94%) than those with longer duration of preoperative symptoms, especially in nonthymomatous patients. Age and sex had no effect on the outcome. There was no effect on response rate if patients had hyperplastic or non-specific thymic histological findings, but patients with thymoma fared worse. Conclusions -These results are comparable with reports from the western world and represent the first prospective study from the Middle East. Thymectomy is indicated for all patients suffering from generalised myasthenia gravis soon after the diagnosis is made, regardless of age, stage, thymic pathology, and preoperative clinical status.
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However, there is still no general agreement about which patients would benefit most from the removal of the thymus.9"0 Our aim was to evaluate the influence of some of the factors known to be controversial for outcome after thymectomy in patients with myasthenia gravis in a Middle East patient population. We were also interested to know the safety and efficacy of this procedure and the clinical course of 63 consecutive patients with myasthenia gravis treated with thymectomy is reviewed.
One important issue is the timing of surgical intervention in these patients. Some of the controversial factors which may have an effect on the outcome in patients with myasthenia gravis undergoing thymectomy were evaluated including age, sex, duration of symptoms, thymic pathology, disease severity, and the amount of preoperative medication.
The diagnosis was established on the basis of history and physical findings, and a positive tensilon (edrophonium) test. In some patients adjuvant diagnostic tests were also used (jolly test, electromyography (EMG), and acetylcholine receptor (AChR) antibody). All patients were evaluated for other possible associated conditions -for example, thyroid auto- The operation was performed through a complete median sternotomy. Mediastinal dissection began from the lowest part of the anterior mediastinum but not beyond the phrenic nerves. If prominent lymph nodes were present around these nerves they were isolated and the lymph nodes and their adjacent fatty tissue included en bloc with the specimen. The dissection continued cephalad until the lower portion of the thyroid was reached. The patients were weaned from the ventilator when continuous pulse oximetry, serial evaluation ofarterial blood gas tensions, lung volume and mechanics, and ability to protect airway or control secretions permitted. The patients were extubated according to the same parameters and his/her response to the weaning process.
Tapering of medications did not have a standard protocol as different strategies were used by the various neurologists involved. In some patients treatment started 1-3 days after surgery and decreased as symptoms decreased, while in others, especially those with more mild disease, the dosage was started as low as possible and increased to an optimum over the hospital stay or next clinical visit and modified again at future visits.
Results
Thirty four of the patients (54%) were women and the age range was 1-5-51 years (mean 25-7). Eight patients were under 15 years of age, of whom four were aged 1 5-4 years. The mean age of the patients older than 15 years was 28-2 (figure). The interval between the onset of symptoms to surgery was 4-180 months (median 21). None required perioperative blood transfusion and the average amount of blood loss was less than 300 ml.
Seven patients with class IIA disease were taking no medication before surgery. Twenty nine patients were treated with neostigmine or pyridostigmine, eight were on steroids, and another 19 were treated by both medications preoperatively.
There was no operative mortality. Forty six patients were extubated in the recovery room, 14 of whom were not admitted to the ICU and were returned to the surgical ward. In seven patients intubation was continued for 1-7 days postoperatively (mean 3-7 days) including the Surgical treatment of myasthenia gravis in two Middle East teaching hospitals 7 The effect of early surgical intervention after the onset of symptoms on the response rate is controversial. In a survey by Lanska" only four of 56 experienced neurologists advocated thymectomy in less than one third of their patients; 28 advocated it for between one third and two thirds, and 17 advocated it for more than two thirds of their patients. Most of the neurologists in that report advocated thymectomy for selected patients with generalised myasthenia gravis without thymoma. Some reports have shown no relation between the preoperative duration of symptoms and the outcome.'8 9 Our results and those of others 2 4 7 15 20 21 show that patients operated on early in the course of their disease have a better outcome. More than 80% of our patients were referred less than three years after the onset of symptoms. Patients operated on later during the study had a significantly shorter duration of symptoms than those seen earlier in the study.
Hatton et al22 and Barton et al 2 reported that patients with more advanced disease benefited more from thymectomy, while others7819 found that the stage of the disease had no effect on outcome. Our results and those of others4 1821 24 suggest a more favourable outcome in patients with a milder form of myasthenia gravis. Patients with advanced disease received more medication when admitted for surgery so a less favourable prognosis in patients on more drugs was attributed to a more advanced stage of the disease and not to the amount of preoperative medication itself.
Compared with most others, who have reported thymoma in 9-28% of their patients with myasthenia gravis, only five (8%) of our patients had a thymoma. In addition, although some authors have shown a better outcome in patients with thymic hyperplasia,22 in our series and others7"5"19-2123 there was no difference in remission or response between patients with germinal layer hyperplasia and those with a non-specific thymic histopathological report.
